What is the Impact Factor of Onkourologiya?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Onkourologiya is 0.10, ranking in quartile Q4 of Web of Science (ESCI).

Is Onkourologiya indexed in Web of Science or Scopus?

Yes, Onkourologiya is indexed in Web of Science (ESCI, Q4 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 0.126 (Q4) and an H-index of 7.

Who publishes Onkourologiya and what is the Article Processing Charge (APC)?

Onkourologiya is published by ABV-press. The estimated Article Processing Charge (APC) is approximately $2,261 USD, subject to institutional waivers and corresponding author affiliations.

WoS ESCI Q4Scopus Q4SCImago #27,677Hybrid

Onkourologiya

Identifier (ISSN):1726-9776(Print)/1996-1812(Online)

•

Publisher:ABV-press

Clarivate JCR Index Advisory: Active (ESCI)

Official Website Submission Portal Compare

Clarivate IF (2026)

0.1– 0

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS ESCIJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2023–2026)

Clarivate IF trend for Onkourologiya

WoS Q4

Annual Impact Factor Metric

Current (2026):0.1

Scopus SJR & RankScopus Q4

0.126

#27,677

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

7 papers with at least that number of citations each

WoS: ESCIQ4

Self-Citation RateN/A

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

73articles/year

92.31% Gold OA•89.71% Original Research

Aims & Scope

The main objective of the journal "Cancer urology" is publishing up-to-date information about scientific clinical researches, diagnostics, treatment of oncologic urological diseases. The aim of the edition is to inform the experts on oncologic urology about achievements in this area, to build understanding of the necessary integrated interdisciplinary approach in therapy, alongside with urologists, combining efforts of doctors of various specialties (cardiologists, pediatricians, chemotherapeutists et al.), to contribute to raising the effectiveness of oncologic patients’ treatment.

Topics Covered (Recognized by AI)

MedicineInternal MedicineBiologyGeneticsOncology & Cancer ResearchOncologyPathologySurgeryRadiologyEndocrinologyChemistryBiochemistry

Primary Research Areas

Oncology

Official Website NLM PubMed Catalog SCImago Profile

0 calls

Special Issues

Calls for Papers

No active Calls for Papers found for this journal.

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRESCI2026

ONCOLOGY

Rank331/333

IndexESCI

JCIESCI2026

ONCOLOGY

Rank331/333

IndexESCI

Category	Index	Rank	Quartile
ONCOLOGY	JCRESCI	331/333	Q4
ONCOLOGY	JCIESCI	331/333	Q4

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF0.1

Articles / Year17

Total Citations1

2025

IF0.1

Articles / Year56

Total Citations11

2024

IF0.1

Articles / Year63

Total Citations27

2023

IF0.1

Articles / Year69

Total Citations46

2022

IF—

Articles / Year72

Total Citations55

Year	Impact Factor	Articles / Year	Total Citations
2026	0.1	17	1
2025	0.1	56	11
2024	0.1	63	27
2023	0.1	69	46
2022	—	72	55
2021	—	86	112
2020	—	82	113
2019	—	77	164
2018	—	76	161
2017	—	73	141
2016	—	60	142
2015	—	60	99

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #27,677Scopus Q4SCImago Profile

Scopus Coverage:2005-2008, 2016-2025

•

Scopus Broad Areas:Medicine

Scopus Citation Rank (SJR)Q4

0.126

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q4

Citations / Doc (2 years)

0.27

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$2,261 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations51

3-Year Documents204

Citable Documents197

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate38.2%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

NephrologyQ4

OncologyQ4

Radiology, Nuclear Medicine and ImagingQ4

SurgeryQ4

UrologyQ4

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: N/A

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

4区 (Zone 4)Medicine

Minor Category (Specific Field):

4区ONCOLOGY

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Onkourologiya (ISSN: 1726-9776) is a peer-reviewed international scholarly journal in the field of ONCOLOGY, published by ABV-press in Russian Federation. The periodical holds a Journal Impact Factor (JIF) of 0.10, ranking in quartile Q4 of Web of Science (ESCI), a Scopus SJR indicator of 0.126 (Q4), an H-index of 7.

The journal enforces rigorous peer evaluation with an annual output of approximately 73 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $2,261 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.